Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by equities research analysts at Jefferies Financial Group from a “buy” ...
The stock's rise snapped a four-day losing streak.
BofA reinstated coverage of Biogen (BIIB) with a Neutral rating and $178 price target Biogen is “a cheaper name,” mostly ...
Shares of Biogen Inc. BIIB slumped 0.84% to $156.46 Monday, on what proved to be an all-around dismal trading session for the ...
As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene ...
In a report released today, Michael Yee from Jefferies downgraded Biogen (BIIB – Research Report) to a Hold, with a price target of ...
We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...
in.investing.com on MSN2d
Biogen cut at Jefferies as '2025 has a tough setup'Jefferies downgraded Biogen (NASDAQ:BIIB) from a Buy to Hold on monday, citing a challenging outlook for 2025. The firm ...
GET MORE AI-GENERATED SIGNALS: November 30, 2024, 22:30 pm ET, BY Rick O.- Contributor| Editor: Thomas H. Kee Jr. ( Follow on ...
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data ...
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Biogen Inc. (BIIB) and Myriad Genetics (MYGN). But which of these two stocks offers value ...
Pick the best stocks and maximize your portfolio: Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback